|
|
Thomson Financial Business Description:
| The Group's principal activity is to develop and market innovative biopharmaceuticals for serious diseases and medical conditions. Its products portfolio comprised of three approved products and multiple investigational product candidates Aldurazyme(R)(laronidase), NaglazymeTM (galsulfase) and Orapred(R)(prednisolone sodium phosphate oral solution) are approved products. The Group also develops several other product candidates for the treatment of genetic diseases including: Naglazyme for the treatment of mucopolysaccharidosis VI (MPS VI); Phenoptin (6R-BH4), a proprietary oral form of tetrahydrobiopterin for the treatment of moderate to mild forms of phenylketonuria (PKU); and Phenylase (recombinant phenylalanine ammonialyase), a preclinical candidate for the treatment of the more severe form of PKU. The Group's trademarks are BioMarin, Phenoptin, Neutralase, Vibrilase, Phenylase, and NeuroTrans. |
|
Alacra Alerts:
 
|
Receive alerts on the latest reports on BioMarin Pharmaceutical Inc.
Subscribe to Alacra Alerts via RSS and never miss the latest research on your favorite companies. Just click the images above to add the feed directly to your favorite newsreader.
|
|
